We would love to hear your thoughts about our site and services, please take our survey here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Has there been any update of how well the company did in 2023 and what the outlook is for 2024 as well any update on new product development etc.
The last real RNS with that type of info was on "27 Sep 2023 - Half-year Report" which covered to 30 June 2023. I'd have thought the full year report would have been released by now.
My wife has been smoking for over 50 years and also hasn't had any side effects yet but not sure that should reassure anyone about the impact of cigarettes. The bottom line is that as LPLDL is clinically proven to lower cholesterol on its own, why persevere with a product containing red yeast at levels considered unsafe by other jurisdictions?
"Q. My bad cholesterol has been rising, and my doctor suggested that I start taking a statin. I've read that red yeast rice has many of the cholesterol-lowering benefits of a statin, and I would rather go the natural route. However, I recently heard on a newscast that red yeast rice can have adverse effects on the kidneys. Is it still safe for me to take this supplement?
A. It's true that red yeast rice, which contains monacolin K, a chemical that's identical to the active ingredient in the cholesterol-lowering drug lovastatin (Mevacor), may reduce your LDL (bad) cholesterol and lower your total cholesterol. However, an independent analysis of a dozen 600-milligram (mg) capsules of red yeast rice products conducted a few years ago found that the actual monacolin K content varied widely — from 0.1 mg to 10.9 mg. (The lowest dose of lovastatin is 20 mg.) In addition, one-third of the products were contaminated with a potentially toxic compound called citrinin, which can damage the kidneys. The Food and Drug Administration (FDA) has blocked the sale of red yeast rice supplements that contain enough of the active ingredient to make them as effective as lovastatin because they haven't undergone the drug approval process. Unlike FDA-approved drugs, supplements can be sold without proof of effectiveness and purity."
https://www.health.harvard.edu/cholesterol/can-i-use-red-yeast-rice-instead-of-a-statin-to-lower-my-cholesterol
I've been using x3 for 1 year now....great product and very effective.
no side effects or issues with it what so ever!
Typical. I bought a box of that the other day
Already banned in US and heavily restricted in the EU, issues now raised in Japan. Amazed PBX still sells Cholbiome X3 in the UK
https://www.bbc.co.uk/news/world-asia-68662585
Today, I sent yet another follow up to this exchange with Walbrook from early Dec.
"Apologies for the delay. I was on holiday when you sent the original email and it fell under my radar after I got back. The Company is working constantly on delivering milestones and increasing liquidity. The latter is difficult in these markets, but they have a defined strategy in place. For your information, we intend to hold an investor presentation (hosted on the IMC platform) in the New Year where Steen will lay out the plans for 2024 and how he and the Board plan to delivery growth."
Got a prompt reply!
"We will be holding an IMC for PBX. And we will let the market know... as soon as we have a date!"
Thanks for putting me straight on this. It is the same company as referred to in half year report.
Thanks BK, translation of the page below
"Dual-Level Support: SymbioLife® Cholesterol Control* provides support to our body on two levels, naturally normalizing cholesterol levels.
It contains the bacterium Lactobacillus plantarum LPLDL®, harnessing the significant impact of natural bacteria on our health. Intestinal bacteria, particularly of the Lactobacillus genus, can regulate our cholesterol levels by binding to cholesterol or incorporating it into their own cell membranes.
The specific intestinal bacterium Lactobacillus plantarum LPLDL® also increases our excretion of bile acids. As a result, our body produces more bile acids, which are essential for fat digestion, and in turn, removes cholesterol from the blood.
In addition to this, SymbioLife® Cholesterol Control contains phytosterols*, secondary plant compounds that possess a structure similar to cholesterol. When we consume phytosterols, our intestinal wall transports them into our body instead of cholesterol.
The remaining cholesterol in the intestine is then excreted with the stool, leading to a decrease in cholesterol levels"
Https://www.symbiopharm.de/produkte/symbiolife-praezisionsprobiotika/symbiolife-cholesterin-control
The rns states...
SymbioPharm has introduced the CholBiome® CH formulation as a premium pharmacy supplement solution across targeted regions...
Sounds like the formulation is already on sale?
Agree Dire, guess we have to wait for the partner to set up its manufacturing capability before an eventual launch then
Also, this shows how agreements on partnerships and commercialisation are like wading through treacle.
So confirmation the agreement has been signed off, albeit a little behind schedule.
Seed Health never announced the outcome of their clinical study into DS01 for treating Irritable Bowel Syndrome despite the clinical study finishing over a year ago so guess may well have been inconclusive which is a pity
Isn't this the same agreement announced in the Sep Results RNS?
" Closing of long-term commercial agreement with third largest supplement brand in Germany. The agreement is aiming at launching CholBiome® CH - our newest product line extension - in Germany during Q4 this year. The launch will eventually be broadened to include Austria and Switzerland."
SymbioPharm's apparent reputation and access to market, incl pharmacies should help sales.
ProBiotix Health plc (AQUIS: PBX), a life sciences business developing probiotics to support cardiometabolic health, announces it has entered into a partnership agreement with SymbioPharm, a German company pioneering in microbiome research and knowledge-based probiotics. SymbioPharm has secured its position as a leading innovator and provider of probiotics, medicinal products and dietary supplements in Germany, Austria and Switzerland where it is considered a top tier consumer brand. SymbioPharm's distribution network spans direct-to-consumer channels as well as a comprehensive online and offline pharmacy presence.
The agreement allows SymbioPharm to utilise ProBiotix's CholBiome® CH formulation to target and reduce cholesterol in their branded consumer products. SymbioPharm has introduced the CholBiome® CH formulation as a premium pharmacy supplement solution across targeted regions. The agreement covers sales in Germany, Austria and Switzerland, focusing on maximising market penetration through strategic pharmacy partnerships.
The unique and innovative formulation developed by ProBiotix comes with a European Food Safety Authority (EFSA) health claim, specific for cholesterol.
Steen Andersen, CEO of ProBiotix Health plc commented: "We are delighted that Symbiopharm, a recognised leader in the probiotic space, has engaged with ProBiotix Health. This collaboration is strategically aligned with our goal of extending the reach of our unique finished product formulations within the DACH region (Germany, Austria and Switzerland). This is an important step for us to further expand our business in the consumer health segment, and allow us to reach a broader audience, enhancing market presence and influence."
Tobias Brodtkorb, CEO of SymbioPharm added: "We are very pleased to have entered into this agreement with ProBiotix Health. We are a collaborative business and are passionate about natural treatments using live bacteria. Our focus is not only on effective therapies, but also on the associated diagnostics and scientific research on the microbiome, and we find our model fits in naturally with ProBiotix and their mission. We are delighted to be working closely with them and hope for a strong relationship going forward."
No not us per se but seed in at no 4 according to Success magazine
Most Innovative Company in Health & Wellness
4. Seed Health Inc.
Who they are: Seed is a direct-to-consumer, research-backed probiotic company whose products are available for a monthly subscription fee of $49.99.
How they innovate: The company believes “the science of probiotics demands a new standard.” Currently, the company offers just two consumer products; however, the science and testing that go into their products is anything but limited. Based on robust clinical research, it collects probiotic strains and puts them to the test in a high-tech simulator known as SHIME®, which mimics biological conditions from stomach to colon. Formula information and testing data are transparent and accessible, and its scientific board includes researchers from the National Institutes of Health’s Human Microbiome Project.
Financials: Seed is a privately held company; revenue and earnings are not publicly available. According to WWD, the company raised $40 million in Series A funding in 2021.
Impact: Seed’s combination of scientific rigor, social impact work and award-winning product design, plus a subscription model that eliminates the overhead of brick-and-mortar retail, make it a standout in an otherwise overcrowded and underregulated supplements industry.
https://www.success.com/most-innovative-companies-2024/
mol
Tom now moved to Business Development Manager, as he is at Optibiotix, from Feb 2024
https://uk.linkedin.com/in/tom-o-hara-6a8686184
I'll just leave it at that
mol
I thought the £1m cost of moving to AIM was an initial figure. Thought SOH said it would be cheaper 18 months (?) after IPO. And if I've remembered correctly, I would support a move to AIM. I don't have loads of spare cash but would happily top up eg monthly at these prices.
There is little if any trading PBX on the Aquis platform.
The spread is horrendous . Up to 4p
There appears to be no access for Aquis Only shares on any international platforms.
The cost to move to AIM is quoted by SOH is up to £1m so based on 125m shares well under 1p for each share.
Liquidity is critical and Aquis does not perform or is ever likely to.
Time for the CEO to find a way out of this quagmire.
NOW!
Another new position.
https://www.linkedin.com/jobs/view/sales-manager-at-probiotix-health-131090497
PBX at Probiota event. From this Wed to Fri.
https://www.linkedin.com/company/probiotix-health?trk=feed_main-feed-card_feed-actor-name
O’Hara should have realised a long time ago that staying on Aquis restricts the share price notably on the spread but particularly that no international brokers include PBX as tradable.
That alone stops interest. Shares that are on Aquis as extra to their AIM listing for example are
unaffected. So for anyone outside UK has only expensive full service brokers to turn to and low flexibility.
It seems to be “Fiddling while Rome burns”
What happens if Probiotix did move to AIM. Would our shares automatically get moved over to AIM?
I currently have mine in a iWeb account, but as they don't offer Aquiss exchange, I would have to move them to a provider who does. I was hoping Probiotix would move to AIM.